GSK to Acquire RAPT Therapeutics for $1.9 Billion
GSK plc (GSK) entered a merger agreement on January 20, 2026, to acquire RAPT Therapeutics, Inc. (RAPT) for $1.9 billion. Deal Structure: GSK will pay RAPT Therapeutics…
Written byAsif SuriaSource: InsideArbitrage
GSK plc (GSK) entered a merger agreement on January 20, 2026, to acquire RAPT Therapeutics, Inc. (RAPT) for $1.9 billion. Deal Structure: GSK will pay RAPT Therapeutics shareholders $58 per share, representing a 65.24% premium from the stock’s last close. Company Profile: RAPT Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel immunology-based therapies,